IMA203 for Skin Cancer
(SUPRAME Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This clinical trial is a prospective, multicenter, open-label, randomized, actively controlled, parallel-group Phase 3 clinical trial to evaluate the efficacy, safety and tolerability of treatment with IMA203 administered at the recommended phase 2 dose versus investigator's choice of treatment in patients with previously treated, unresectable or metastatic cutaneous melanoma.
Do I need to stop my current medications to join the trial?
The trial protocol does not specify if you need to stop taking your current medications. However, you cannot have received systemic corticosteroids within 2 weeks before a certain procedure, or any anti-cancer therapy or radiotherapy within 1 week before starting the trial treatment.
Is IMA203 safe for treating skin cancer?
What data supports the effectiveness of the treatment IMA203 for skin cancer?
Research shows that imiquimod, a component used in similar treatments, has been effective in treating various skin cancers, including basal cell carcinoma and melanoma, by boosting the immune response to fight cancer cells. This suggests that treatments like IMA203, which may involve similar mechanisms, could potentially be effective for skin cancer.36789
Who Is on the Research Team?
Cedrik Britten, M.D.
Principal Investigator
Immatics US, Inc.
Are You a Good Fit for This Trial?
This trial is for adults with confirmed cutaneous melanoma that's spread and can't be removed by surgery. They must have tried a PD-1 inhibitor treatment before, have good organ function, and an ECOG status of 0-1 (which means they're fully active or restricted in physically strenuous activity but can do light work). Women who can have children and men must agree to use contraception.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Manufacturing
IMA203 products will be made from the patients' white blood cells
Treatment
Lymphodepletion with cyclophosphamide and fludarabine followed by IMA203 infusion and low dose IL-2 for up to 10 days
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- IMA203
Find a Clinic Near You
Who Is Running the Clinical Trial?
Immatics US, Inc.
Lead Sponsor